{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:14Z","timestamp":1792788074225,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["R25TW009340"],"award-info":[{"award-number":["R25TW009340"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"],"award-info":[{"award-number":["5T32 CA09071; R01CA250069; R21CA232891; P30CA006973, P30AI094189"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1CA121947"],"award-info":[{"award-number":["UM1CA121947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1CA121947"],"award-info":[{"award-number":["UM1CA121947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ILEAD initiative"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prospective data from sub-Saharan Africa suggests that treatment outcomes for people living with HIV (PWH) with Hodgkin lymphoma (HL) are similar to those without HIV. However, real-world data from high-resource settings and retrospective studies from sub-Saharan Africa, suggest inferior outcomes. We set out to evaluate the real-world treatment outcomes for HL in South Africa to better understand the disparate outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established a prospective, observational cohort of newly diagnosed, adult (\u2265\u200918\u00a0years) HL cases recruited from Chris Hani Baragwanath Academic and Netcare Olivedale Hospitals in Johannesburg, South Africa between March 2021 and March 2023. Participants were followed for up to 18\u00a0months after enrollment with data censored on December 23rd, 2023. The primary endpoint was 1-year overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We enrolled 47 participants with HL including 31 PWH and 16 HIV-negative. Advanced stage disease and B symptoms were common at time of diagnosis irrespective of HIV status. Bone marrow biopsy, performed during the work-up and evaluation of cytopenias, provided the initial diagnosis of HL in 16\/31 (52%) PWH. HIV status and bone marrow involvement were associated with early mortality (within 3\u00a0months of diagnosis) and a poorer 1-year overall survival from diagnosis (HIV: 55% vs. 88%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03; bone marrow involvement: 50% vs. 80%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Among evaluable participants, those that received at least 6 cycles of chemotherapy and underwent response assessment, there was no difference between those with and without HIV.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Traditional laboratory markers of poor prognosis including anemia, lymphopenia and hypoalbuminemia were more common among PWH and those with bone marrow involvement and suggest high risk disease. A better understanding of the drivers of these aggressive presentations is warranted to ensure more PWH are able to tolerate chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13027-024-00612-4","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:02:34Z","timestamp":1727416954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study"],"prefix":"10.1186","volume":"19","author":[{"given":"Samantha L.","family":"Vogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrick","family":"Laudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Lakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugeshnee","family":"Pather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyaad","family":"Waja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deshan","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvier","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Ashmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy","family":"Otwombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuthadzo","family":"Hlongwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena R.","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinitha","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"5","key":"612_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/QAI.0b013e3181b327ca","volume":"52","author":"MS Shiels","year":"2009","unstructured":"Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52(5):611\u201322.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"612_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186549","volume":"12","author":"A Cingolani","year":"2017","unstructured":"Cingolani A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE. 2017;12(10): e0186549.","journal-title":"PLoS ONE"},{"issue":"15","key":"612_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","volume":"28","author":"TM Gibson","year":"2014","unstructured":"Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313\u20138.","journal-title":"AIDS"},{"issue":"12","key":"612_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/jnci\/djm010","volume":"99","author":"Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, Study HACM","year":"2007","unstructured":"Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, Study HACM. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962\u201372.","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"612_CR5","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","volume":"113","author":"GM Clifford","year":"2009","unstructured":"Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, et al. Hodgkin lymphoma in the Swiss HIV cohort study. Blood. 2009;113(23):5737\u201342.","journal-title":"Blood"},{"issue":"4","key":"612_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/QAI.0000000000002276","volume":"83","author":"J Vaughan","year":"2020","unstructured":"Vaughan J, Perner Y, McAlpine E, Wiggill T. Brief report: HIV-associated Hodgkin lymphoma involving the bone marrow identifies a very high-risk subpopulation in the era of widescale antiretroviral therapy use in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020;83(4):345\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"612_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/578163","volume":"2011","author":"M Patel","year":"2011","unstructured":"Patel M, Philip V, Fazel F. Human immunodeficiency virus infection and Hodgkin\u2019s lymphoma in South Africa: an emerging problem. Adv Hematol. 2011;2011: 578163.","journal-title":"Adv Hematol"},{"issue":"2","key":"612_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00277-018-3533-0","volume":"98","author":"L Swart","year":"2019","unstructured":"Swart L, Novitzky N, Mohamed Z, Opie J. Hodgkin lymphoma at Groote Schuur hospital, South Africa: the effect of HIV and bone marrow infiltration. Ann Hematol. 2019;98(2):381\u20139.","journal-title":"Ann Hematol"},{"issue":"9","key":"612_CR9","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1093\/cid\/civ627","volume":"61","author":"C Besson","year":"2015","unstructured":"Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, et al. High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART Era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis. 2015;61(9):1469\u201375.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"612_CR10","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.3324\/haematol.2012.079921","volume":"98","author":"B Xicoy","year":"2013","unstructured":"Xicoy B, Miralles P, Morgades M, Rubio R, Valencia ME, Ribera JM. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin\u2019s lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. Haematologica. 2013;98(8):e85\u20136.","journal-title":"Haematologica"},{"key":"612_CR11","doi-asserted-by":"crossref","unstructured":"Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23(2):274\u201381.","DOI":"10.1158\/1055-9965.EPI-13-0865"},{"issue":"15","key":"612_CR12","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.23.02366","volume":"42","author":"JK McGee-Avila","year":"2024","unstructured":"McGee-Avila JK, Suneja G, Engels EA, Rositch AF, Horner MJ, Luo Q, et al. Cancer treatment disparities in people with HIV in the United States, 2001\u20132019. J Clin Oncol. 2024;42(15):1810\u201320.","journal-title":"J Clin Oncol"},{"key":"612_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00163","volume":"8","author":"K Moahi","year":"2022","unstructured":"Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A, Musimar Z, et al. HIV and Hodgkin lymphoma survival: a prospective study in Botswana. JCO Glob Oncol. 2022;8: e2100163.","journal-title":"JCO Glob Oncol"},{"key":"612_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102480","volume":"69","author":"M Mponda","year":"2024","unstructured":"Mponda M, Kudowa E, Craven DM, Eastburg LC, Chikasema M, Kasonkanji E, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. EClinicalMedicine. 2024;69: 102480.","journal-title":"EClinicalMedicine"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.anndiagpath.2019.02.001","volume":"39","author":"DP O'Malley","year":"2019","unstructured":"O\u2019Malley DP, Dogan A, Fedoriw Y, Medeiros LJ, Ok CY, Salama ME. American Registry of Pathology Expert Opinions: immunohistochemical evaluation of classic Hodgkin lymphoma. Ann Diagn Pathol. 2019;39:105\u201310.","journal-title":"Ann Diagn Pathol"},{"issue":"27","key":"612_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"key":"612_CR17","doi-asserted-by":"crossref","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506\u201314.","DOI":"10.1056\/NEJM199811193392104"},{"key":"612_CR18","unstructured":"Fry KFR, Chakraborty NM. Measuring equity with nationally representative wealth quintiles. 2014 [Available from: https:\/\/media.psi.org\/wp-content\/uploads\/2020\/02\/31012157\/Wealth-Quintile-Guide.pdf."},{"key":"612_CR19","unstructured":"Rutstein SO. Steps to constructing the new DHS Wealth Index. Rockville, MD: ICF International. 2015;6."},{"issue":"282","key":"612_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EM Kaplan","year":"1958","unstructured":"Kaplan EM, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"612_CR21","doi-asserted-by":"crossref","unstructured":"Brookmeyer RC, J.J. A confidence interval for the median survival time. Biometrics. 1982;38:29.","DOI":"10.2307\/2530286"},{"key":"612_CR22","doi-asserted-by":"crossref","unstructured":"Rubio R. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative study group of malignancies associated with HIV infection of Madrid. Cancer. 1994;73(9):2400\u20137.","DOI":"10.1002\/1097-0142(19940501)73:9<2400::AID-CNCR2820730925>3.0.CO;2-C"},{"issue":"4","key":"612_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101514","volume":"36","author":"R Masel","year":"2023","unstructured":"Masel R, Roche ME, Martinez-Outschoorn U. Hodgkin lymphoma: a disease shaped by the tumor micro- and macroenvironment. Best Pract Res Clin Haematol. 2023;36(4): 101514.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"612_CR24","volume":"14","author":"T Dasaradhan","year":"2022","unstructured":"Dasaradhan T, Koneti J, Kalluru R, Gadde S, Cherukuri SP, Chikatimalla R. Tuberculosis-associated anemia: a narrative review. Cureus. 2022;14(8): e27746.","journal-title":"Cureus"},{"key":"612_CR25","doi-asserted-by":"crossref","unstructured":"Vellemans H, Andre MPE. Review of treatment options for the management of advanced stage Hodgkin lymphoma. Cancers. 2021;13(15).","DOI":"10.3390\/cancers13153745"},{"issue":"5","key":"612_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/QAD.0000000000000986","volume":"30","author":"AJ Olszewski","year":"2016","unstructured":"Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016;30(5):787\u201396.","journal-title":"AIDS"},{"issue":"2","key":"612_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/10408363.2017.1422692","volume":"55","author":"R Grewal","year":"2018","unstructured":"Grewal R, Irimie A, Naidoo N, Mohamed N, Petrushev B, Chetty M, et al. Hodgkin\u2019s lymphoma and its association with EBV and HIV infection. Crit Rev Clin Lab Sci. 2018;55(2):102\u201314.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"612_CR28","doi-asserted-by":"crossref","unstructured":"Lupo J, Truffot A, Andreani J, Habib M, Epaulard O, Morand P, et al. Virological Markers in Epstein-Barr Virus-Associated Diseases. Viruses. 2023;15(3).","DOI":"10.3390\/v15030656"},{"issue":"8","key":"612_CR29","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1182\/bloodadvances.2020001511","volume":"4","author":"M Shamay","year":"2020","unstructured":"Shamay M, Kanakry JA, Low JSW, Horowitz NA, Journo G, Ahuja A, et al. CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma. Blood Adv. 2020;4(8):1624\u20137.","journal-title":"Blood Adv"},{"issue":"1","key":"612_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1186\/s12885-024-12569-z","volume":"24","author":"MM Mbai","year":"2024","unstructured":"Mbai MM, Mduma E, Thuo S, Rugengamanzi E, Malichewe CV, Lugina EL. A comparison of clinical profile and treatment outcome of Hodgkin\u2019s Lymphoma in Tanzania according to HIV status during the HAART era. BMC Cancer. 2024;24(1):796.","journal-title":"BMC Cancer"},{"issue":"8","key":"612_CR31","doi-asserted-by":"publisher","first-page":"e624","DOI":"10.1016\/S2352-3026(23)00157-6","volume":"10","author":"PG Rubinstein","year":"2023","unstructured":"Rubinstein PG, Moore PC, Bimali M, Lee JY, Rudek MA, Chadburn A, et al. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1\/2 trial. Lancet Haematol. 2023;10(8):e624\u201332.","journal-title":"Lancet Haematol"},{"key":"612_CR32","doi-asserted-by":"crossref","unstructured":"Herrera AF, LeBlanc ML, Castellino SM, Li H, Rutherford SC, Evens AM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). Journal of Clinical Oncology. 2023;41(17_suppl):LBA4-LBA.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1182\/blood-2023-190513","volume":"142","author":"A Graeter","year":"2023","unstructured":"Graeter A, Bowles KE, Coghill A. Safety and efficacy of immune checkpoint inhibitors in the treatment of hodgkin lymphoma in people living with human immunodeficiency virus: a case series. Blood. 2023;142:6176.","journal-title":"Blood"},{"issue":"10","key":"612_CR34","first-page":"1393","volume":"36","author":"SL Vogt","year":"2022","unstructured":"Vogt SL, Maloma L, Xian RR, Ambinder RF, Philip V, Patel M, et al. Significance of lymph node fine needle aspiration for the diagnosis of HIV-associated lymphoma in a low-resource setting. AIDS. 2022;36(10):1393\u20138.","journal-title":"AIDS"},{"issue":"4","key":"612_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.seminhematol.2023.08.005","volume":"60","author":"S Gopal","year":"2023","unstructured":"Gopal S. The case for prioritizing malignant hematology services in low- and middle-income countries. Semin Hematol. 2023;60(4):189\u201391.","journal-title":"Semin Hematol"}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00612-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00612-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00612-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:17:08Z","timestamp":1727417828000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00612-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00612-4","relation":{},"ISSN":["1750-9378"],"issn-type":[{"value":"1750-9378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Johns Hopkins School of Medicine Institutional Review Board (IRB00107027) and the University of the Witwatersrand Human Research Ethics Committee (200208).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}